Lone Dahl Andersen

Lone Dahl Andersen has extensive experience within financial functions and financial management from both a general audit consulting company and the international pharmaceutical and biotech industry and holds an HDR, Graduate Diploma in Business Administration, Financial and Managements Accounting. Mrs. Andersen has operational and hands-on experience in building a finance department across different cultures and set-ups and has a proven track record in alliance management, business development, having been responsible for the financial part of preparing and facilitating a merger of two international pharmaceutical companies, Sanofi and Synthelabo. Was instrumental in the merger between two public listed international biotech companies, Topotarget A/S and BioAlliance Pharma S.A

Position	CFO since 2019 - CEO since 2020
Year of Birth	1960
Holding of shares in Cytovac AB (as of Dec 31, 2020)	None
Other ongoing assignments	Lone Dahl Andersen does not have other ongoing assignments.
Previous Assignments (within the last 5 years)	Director of Finance at Topotarget A/S/Onxeo DK (merged company).
Independent in relation to the company and its management	Yes
Independent in relation to larger shareholders	Yes